https://sciex.com/content/SCIEX/na/us/en


5 Reasons to choose the Echo® MS system for high-throughput drug discovery

Mar 22, 2023 | Blogs, Discovery, Echo MS, Pharma | 0 comments

Read time: 1 min

Have you thought about introducing new technology into your high-throughput drug discovery lab? Here are 5 reasons the Echo® MS system could make a difference for you.

 

1. Increased sample throughput
While a traditional fast LC-MS/MS run can take nearly 10 hours per plate, a 384-well plate of samples can take approximately 10 minutes per plate with the Echo® MS system. This means that study data can be available on the day samples are prepared and with the reliability of MS/MS.

2. Reduced carryover
Moving away from LC-MS/MS eliminates the challenge of potential carryover. Acoustic Droplet Ejection technology removes the need for physical contact between the autosampler needle and the sample.

3. Method sensitivity
Detection levels in the low nanomolar range are typically required in a high-throughput drug discovery lab and are readily achieved by the Echo® MS system.

4. Sample preparation savings
Simply prepare the samples in an appropriate solvent and load them into a qualified microplate. Only 2.5 nL of precious sample is required for each analysis.

5. Data accuracy
The Echo® MS system uses the trusted SCIEX Triple Quad 6500+ mass spectrometer to provide excellent Z’ values with MS/MS reliability.

Learn more about how the Echo® MS system can support high-throughput drug discovery in these technical notes Development of an acetylcholinesterase biochemical assay using the SCIEX Echo® MS system, Accelerating synthetic biology with very fast screening of metabolites in fermentation broth (sciex.com) might be of interest. Or visit sciex.com.

Is “right first time, every time” a pipedream for metabolite identification by LC-MS?

If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery.

Supporting new CRISPR gene editing systems

Prime editing (PE) is a next-generation gene editing technology that utilizes a Cas9 protein fused to a prime editing guide ribonucleic acid (pegRNA) to achieve high CRISPR/Cas9 editing efficiency and precision. However, the length requirement of pegRNAs at 120–250 nucleotides (nt) and their high level of secondary structure formation present analytical challenges for the purity analysis of chemically synthesized pegRNAs during development and quality control (QC).

A new approach for comprehensive AAV evaluation including full and empty analysis

Certain next-gen vaccines and gene therapy applications rely on the usage of adeno-associated viruses (AAV) as a delivery vehicle. To ensure the safety and efficacy of viral vector drugs, multiple critical quality attributes (CQAs) need to be well characterized.

Posted by

Kirsten Craven is the Senior Global Marketing Manager for Pharma global strategic marketing at SCIEX. In this role, she manages strategic marketing for the pharmaceutical industry. Kirsten spent the first part of her career working in laboratories across multiple industries before moving into product management, and most recently pharma marketing.

Tags


0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial